Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma (R/R MM)

During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.

In this episode of Targeted Talks, Ben Derman, MD, dissects the latest advancements in myeloma treatment, focusing on the role of ClonoSeq and minimal residual disease monitoring.

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.